Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, Lee SH, Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY.
Shen J, et al. Among authors: shin s.
J Immunother Cancer. 2024 Feb 14;12(2):e008339. doi: 10.1136/jitc-2023-008339.
J Immunother Cancer. 2024.
PMID: 38355279
Free PMC article.